Injectable Therapeutic Peptides-An Adjunct to Regenerative Medicine and Sports Performance?

Compound: Sermorelin Citation: DeFoor MT, Dekker TJ. Arthroscopy. 2025;41(2):150-152. doi:10.1016/j.arthro.2024.09.005

Summary

A short (three-page) commentary in Arthroscopy, indexed on PubMed as a review/letter. It is not a trial and reports no new data. Writing as orthopaedic surgeons and team physicians, the authors note that athletes and bodybuilders are turning to injectable peptides to speed recovery and return from injury. They point to very early in-vivo work putting BPC-157 at the forefront, and stress that clinical orthopaedic evidence for these peptides is scarce. The abstract does not name sermorelin.

Key Findings

• Injectable peptides are a new, trending therapy among high-level athletes and bodybuilders seeking to enhance recovery and expedite return from injury, with interest in joint injuries and osteoarthritis
• Very early in-vivo pharmacokinetic research suggests BPC-157 is at the forefront of therapeutic peptides, with early demonstrations related to endurance training, metabolism, recovery, and tissue repair
• Orthopaedic literature on the clinical use and outcomes of these peptides in tendon, muscle, and cartilage injury is scarce
• The peptides are unregulated yet readily available online, and the industry developing them is growing rapidly
• The authors urge orthopaedic surgeons and team physicians to stay current on pharmacokinetic, safety, ethical, legal, and regulatory profiles, because patients will ask about results, risks, and benefits

Relevance to Sermorelin

The commentary addresses injectable therapeutic peptides as a class and names only BPC-157 in its abstract. For sermorelin it is context, not evidence: it underlines how little orthopaedic clinical data exists for injectable peptides used for recovery and performance.

PubMed

See Also

• Parent compound: Sermorelin
• CJC-1295
• Ipamorelin
• Tesamorelin
• BPC-157
• TB-500
• GHK-Cu